^
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pyrotinib
Sensitive: B - Late Trials
Clin Cancer Res - 2 weeks - (New C3)
PIK3CA mutation
HER2 Positive Breast Cancer
THP
Sensitive: C3 – Early Trials
Cancers (Basel) - 1 week - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
HR positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HR positive
HER2 Positive Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
TCHP
Sensitive: A2 - Guideline
ER positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + abemaciclib
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
TCH
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
HR positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A2 - Guideline
HR negative
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab
Sensitive: A2 - Guideline
HR positive
HER2 Positive Breast Cancer
lapatinib
Sensitive: A2 - Guideline
HR positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
HER2 inhibitor
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
AC-TH
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
lapatinib
Sensitive: A2 - Guideline
HR positive
HER2 Positive Breast Cancer
HER2 inhibitor
Sensitive: A2 - Guideline
HR positive
HER2 Positive Breast Cancer
HER2 inhibitor + Aromatase inhibitor
Sensitive: A2 - Guideline
ER positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
AC-THP
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
TH
Sensitive: A2 - Guideline
HR positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
HR positive
HER2 Positive Breast Cancer
Aromatase inhibitor
Sensitive: A2 - Guideline
PIK3CA E545
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
pyrotinib
Sensitive: B - Late Trials
PIK3CA G1049R
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: B - Late Trials
HR negative
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: B - Late Trials
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
HR positive
HER2 Positive Breast Cancer
trastuzumab + neratinib
Sensitive: B - Late Trials
ER positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
ADRB2 overexpression
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
PIK3CA mutation
HER2 Positive Breast Cancer
neratinib
Resistant: B - Late Trials
PIK3CA mutation
HER2 Positive Breast Cancer
lapatinib
Resistant: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine + pertuzumab
Sensitive: B - Late Trials
PD-L1-H
HER2 Positive Breast Cancer
trastuzumab
Resistant: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
tucatinib
Sensitive: B - Late Trials
PD-1 overexpression
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
MYBL2 overexpression
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
PIK3CA mutation
HER2 Positive Breast Cancer
trastuzumab
Resistant: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: B - Late Trials
PIK3CA E542K
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
ERBB3 expression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
SYD985
Sensitive: B - Late Trials
PIK3CA mutation
HER2 Positive Breast Cancer
everolimus
Sensitive: B - Late Trials
PTEN deletion
HER2 Positive Breast Cancer
everolimus
Sensitive: B - Late Trials
PTEN expression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Resistant: B - Late Trials
EGFR expression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: B - Late Trials
PIK3CA M1043I
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
PIK3CA H1047
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: B - Late Trials
HER-2 overexpression
HER2 Positive Breast Cancer
lapatinib
Sensitive: B - Late Trials
PIK3CA Q546
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
TX05 (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
EG12014 (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: B - Late Trials
ACTA2 elevation
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
FCGR3A 158F
HER2 Positive Breast Cancer
margetuximab
Sensitive: B - Late Trials
FCGR3A 158V
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Hervelous (trastuzumab biosimilar)
Sensitive: B - Late Trials
PGR positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
ER positive + PGR positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
HR positive
HER2 Positive Breast Cancer
palbociclib
Sensitive: C1 - Off-label
HR positive
HER2 Positive Breast Cancer
carboplatin + gemcitabine
Sensitive: C2 – Inclusion Criteria
HER-2 expression
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
margetuximab + MGD013
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
PRS-343
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria